Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases.
By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238 million from investors such as RA Capital, Polaris Partners, Perceptive Advisors, Andrees...
Freenome is building technology to gain an understanding of the body through several analytes derived from blood. These signals include cell-free DNA, methylation of cell-free DNA, cell-free RNA, circulating proteins, and immune profiling derived from thousands of prospective samples. By developing novel statistical...